Krystal Biotech, Inc.

Overview

Krystal Biotech, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, specializing in the development of genetic medicines for severe and rare diseases. The company’s expertise centers around redosable gene therapies using a proprietary herpes simplex virus type 1 (HSV-1) vector platform to deliver therapeutic genes to target cells across various organ systems.

The first commercial product, VYJUVEK® (bercolagene telserpavec), is a redosable gene therapy approved for treating dystrophic epidermolysis bullosa, a rare genetic skin disorder. Krystal Biotech is further advancing a pipeline of genetic therapies addressing other serious diseases with high unmet needs. With in-house cGMP facilities, the company delivers end-to-end gene therapy manufacturing and commercialization services for patients, healthcare providers, and pharmaceutical partners in North America and Europe.

Basic Information

Contact Details

• Phone: +1 412-586-5830
• Website: krystalbio.com
• LinkedIn: linkedin.com/company/krystal-biotech-inc

Key Focus Areas & Initiatives

• Next-generation gene delivery
• Gene therapy platform
• Non-integrating vectors
• Gene editing
• Biotech commercialization
• Biotech IPO
• Viral vector engineering
• Gene therapy for lung diseases
• Engineered viral vectors
• HSV-1 based gene therapy
• Rare disease treatment
• Biotech innovation platform
• AAV vectors
• Gene therapy for genetic skin disorders
• Gene therapy regulatory pathway
• Therapeutic platform
• Immune evasion vectors
• Pharmaceuticals
• Gene delivery
• Gene therapy for orphan diseases
• Viral vector platform technology
• High payload gene vectors
• Genetic correction
• Viral vector platform
• GMP facilities
• Medical innovation
• Gene therapy manufacturing
• Biopharmaceuticals
• Gene therapy for rare genetic disorders
• Biotech therapeutics
• Episomal gene delivery
• Scalable manufacturing
• Global biotech
• Gene therapy for dermatology
• Gene delivery technology
• Gene correction
• Biotech global expansion
• Medical research
• Patient-centric biotech solutions
• Biotech collaboration
• Viral vector design
• Non-invasive administration
• Genetic delivery
• Genetic payload capacity
• Patient-specific gene therapy
• Biotech investment
• Genetic medicine for severe diseases
• Non-invasive gene therapy
• Rare diseases research
• Biotech regulatory approval
• Genetic medicines
• Clinical pipeline development
• Large payload capacity vectors
• Gene therapy manufacturing scale-up
• Clinical development
• HSV-1 vector technology
• Viral vector stability
• GMP manufacturing capabilities
• Gene therapy for skin diseases
• Redosable gene therapy
• Gene therapy clinical trials
• Biotech research and development
• AAV alternative vectors
• Repeat dosing gene therapy
• Patient treatment solutions
• Drug development
• Genetic disease treatment
• Clinical-stage biotech innovation
• Vector optimization
• Reliable gene therapy manufacturing
• Gene therapy for ophthalmology
• Research and development in the life sciences
• Dermatology research
• Oncology
• Cosmetics
• Health, wellness & fitness
• Medical and hospital & health care
• Beauty
• Apparel & fashion (biotech applications)

Technologies Used

• AI
• Android
• CSC Corporate Domains
• Microsoft Office 365
• Outlook
• Remote
• Viewpoint

Affiliated Organizations & Regional Branches